Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and …
T Kuhnt, A Schreiber, A Pirnasch… - Strahlentherapie …, 2017 - search.proquest.com
Background Cetuximab (CET) is a potent inhibitor of the epidermal growth factor receptor
and has been shown to have activity in squamous cell carcinoma of the head and neck …
and has been shown to have activity in squamous cell carcinoma of the head and neck …
[HTML][HTML] Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell …
T Kuhnt, A Sandner, T Wendt, R Engenhart-Cabillic… - Annals of oncology, 2010 - Elsevier
Background Cetuximab is active in the treatment of squamous cell carcinoma of the head
and neck (SCCHN), enhancing both radiotherapy and chemotherapy effects. This phase I …
and neck (SCCHN), enhancing both radiotherapy and chemotherapy effects. This phase I …
Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck …
T Kuhnt, A Sandner, TG Wendt… - Journal of Clinical …, 2008 - ascopubs.org
6029 Background: Cetuximab is a potent inhibitor of the epidermal growth factor receptor
and has shown activity in squamous cell carcinoma of the head and neck (SCCHN) …
and has shown activity in squamous cell carcinoma of the head and neck (SCCHN) …
Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
J Bernier, D Schneider - European Journal of Cancer, 2007 - Elsevier
Radiotherapy remains the foundation of current treatment for patients with locally advanced
squamous cell carcinoma of the head and neck (SCCHN). It has been shown that the …
squamous cell carcinoma of the head and neck (SCCHN). It has been shown that the …
Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck
S Okano, T Yoshino, M Fujii, Y Onozawa… - Japanese journal of …, 2013 - academic.oup.com
Background We investigated the tolerability of cetuximab plus radiotherapy in Japanese
patients with untreated locally advanced squamous cell carcinoma of the head and neck …
patients with untreated locally advanced squamous cell carcinoma of the head and neck …
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a …
DG Pfister, YB Su, DH Kraus, SL Wolden… - Journal of clinical …, 2006 - ascopubs.org
Purpose Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …
Final results of a randomized phase 2 trial investigating the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation for …
TY Seiwert, JM Melotek, EA Blair, KM Stenson… - International Journal of …, 2016 - Elsevier
Purpose The role of cetuximab in the treatment of locoregionally advanced head and neck
squamous cell cancer (LA-HNSCC) remains poorly defined. In this phase 2 randomized …
squamous cell cancer (LA-HNSCC) remains poorly defined. In this phase 2 randomized …
[HTML][HTML] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner, PM Harari, J Giralt, N Azarnia… - … England Journal of …, 2006 - Mass Medical Soc
Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …
Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with …
JA Bonner, PM Harari, J Giralt, N Azarnia… - Journal of Clinical …, 2004 - ascopubs.org
5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …
Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma
DJ Thomson, KF Ho, L Ashcroft, K Denton, G Betts… - Acta …, 2015 - Taylor & Francis
Background. For stage II and III head and neck squamous cell carcinoma (HNSCC) treated
with radiotherapy alone, loco-regional recurrence is the main cause of treatment failure …
with radiotherapy alone, loco-regional recurrence is the main cause of treatment failure …
相关搜索
- inoperable squamous cell carcinoma
- head and neck radiation therapy
- head and neck cisplatin chemotherapy
- head and neck concomitant cetuximab
- cell carcinoma synchronous cetuximab
- cell carcinoma stage head
- head and neck survival in patients
- head and neck japanese patients
- chemoradiotherapy for patients cell carcinomas
- cetuximab in locally advanced head
- radiotherapy hart cell head
- concurrent cetuximab cell head
- addition of cetuximab neck cancer
- hyperfractionated chemoradiation neck cancer
- induction chemotherapy neck cancer
- pilot phase cell head